REYVOW Drug Patent Profile

Which patents cover Reyvow, and what generic alternatives are available?

Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty-seven patent family members in forty-seven countries.

The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.

DrugPatentWatch^® Generic Entry Outlook for Reyvow

Reyvow was eligible for patent challenges on January 31, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 5, 2037. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for REYVOW

International Patents:	187
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	84
Drug Prices:	Drug price information for REYVOW
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for REYVOW
What excipients (inactive ingredients) are in REYVOW?	REYVOW excipients list
DailyMed Link:	REYVOW at DailyMed

See drug prices for REYVOW

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for REYVOW

NDA:

211280

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for REYVOW

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
REYVOW	Tablets	lasmiditan succinate	50 mg and 100 mg	211280	1	2024-01-31

US Patents and Regulatory Information for REYVOW

REYVOW is protected by four US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-001	Jan 31, 2020		RX	Yes	No			Y	Y
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-002	Jan 31, 2020		RX	Yes	Yes
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-001	Jan 31, 2020		RX	Yes	No			Y
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-003	Dec 18, 2020		DISCN	Yes	No			Y	Y
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-002	Jan 31, 2020		RX	Yes	Yes			Y	Y
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-003	Dec 18, 2020		DISCN	Yes	No

Expired US Patents for REYVOW

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-001	Jan 31, 2020
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-003	Dec 18, 2020
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-002	Jan 31, 2020

International Patents for REYVOW

When does loss-of-exclusivity occur for REYVOW?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Moldova, Republic of

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering REYVOW around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2021014139
South Africa	202303699
Lithuania	3551617
China	107412230
Croatia	P20040883	PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS
Japan	7566996

Supplementary Protection Certificates for REYVOW

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2413933	2390001-2	Sweden		PRODUCT NAME: LASMIDITAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1587 20220819
2413933	CA 2023 00001	Denmark		PRODUCT NAME: LASMIDITAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1587 20220819
2413933	2023C/503	Belgium		PRODUCT NAME: LASMIDITAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1587 20220819
2413933	PA2023502,C2413933	Lithuania		PRODUCT NAME: LASMIDITANAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/21/1587 20220817
2413933	SPC/GB23/001	United Kingdom		PRODUCT NAME: LASMIDITAN; REGISTERED: UK EU/1/21/1587(FOR NI) 20220819
2413933	C202330007	Spain		PRODUCT NAME: LASMIDITAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/21/1587; DATE OF AUTHORISATION: 20220817; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1587; DATE OF FIRST AUTHORISATION IN EEA: 20220817

Market Dynamics and Financial Trajectory for REYVOW (Lasmiditan)

Last updated: July 27, 2025

Introduction

ReyVow (lasmiditan), developed by Eli Lilly and Company, represents a significant advancement in acute treatment options for migraine sufferers. Approved by the U.S. Food and Drug Administration (FDA) in 2019, ReyVow belongs to the selective serotonin receptor agonist class, primarily designed to provide relief without vasoconstriction, thus offering an alternative for patients contraindicated for triptans. An understanding of the market dynamics and financial trajectory surrounding ReyVow is crucial for stakeholders, including investors, healthcare providers, and competitors, as it informs strategic planning within the rapidly evolving migraine therapeutics landscape.

Market Overview and Growth Drivers

Global Migraine Treatment Market

The global migraine treatment market is projected to expand at a compounded annual growth rate (CAGR) of approximately 5-7% through 2028, driven by increasing prevalence, rising awareness, and the advent of novel therapeutics [1]. Globally, migraine affects over 1 billion individuals, with significant socio-economic burdens attributable to lost productivity and healthcare costs.

ReyVow’s Niche and Innovation

ReyVow targets a specific subset of migraine patients—those with contraindications to triptans, such as cardiovascular disease. Its unique mechanism of action solely on serotonin (5-HT1F receptor) minimizes vasoconstrictive effects, providing a critical treatment option. This positions ReyVow as a niche yet potentially high-growth product within a broader portfolio of migraine therapeutics.

Market Penetration and Adoption Dynamics

Physician and Patient Adoption

Despite FDA approval, ReyVow's market penetration remains gradual. Key factors influencing adoption include:

• Efficacy compared to existing formulations: Clinical trials demonstrate non-inferiority in pain relief, but real-world data remains limited.
• Safety profile: The absence of vasoconstriction indicates a safer profile for high-risk patients.
• Prescriber familiarity and comfort: As a newer agent, clinician education and guidelines influence prescribing behaviors.
• Cost and insurance coverage: Reimbursement policies significantly impact accessibility and patient uptake.

Current estimates suggest that between 10-15% of migraine patients eligible for acute treatment might adopt ReyVow within the first five years post-launch, contingent on market entry strategies and competitive dynamics [2].

Competitive Landscape

ReyVow’s principal competitors include triptans, gepants (ubrogepant, rimegepant), and emerging CGRP monoclonal antibodies. While triptans dominate as first-line therapy, gepants have gained traction due to their similarly favorable safety profiles and oral administration. ReyVow’s unique positioning offers an alternative for patients with contraindications, yet competition remains intense, especially as gepants continue to expand their market share.

Financial Trajectory and Revenue Forecasts

Revenue Drivers

ReyVow’s revenue relies on multiple factors:

• Market uptake in targeted populations
• Pricing strategy and reimbursement negotiations
• Physician and patient acceptance
• Competitive pressures impacting market share

Forecasted Revenue

Based on current data, Eli Lilly projects ReyVow to generate between $200 million and $500 million globally within the first five years, assuming successful market penetration and favorable reimbursement. Analysts estimate annual revenues could reach approximately $150-200 million in the U.S. alone by year 3, with potential for growth in international markets as approval expands.

Cost Considerations

Key costs affecting financial trajectory include:

• Research and development (R&D): Ongoing studies to establish long-term safety and effectiveness.
• Marketing and education: Critical for clinician and patient awareness.
• Manufacturing and supply chain: Ensuring scalable production to meet demand.

Regulatory and Market Challenges

Regulatory Landscape

While FDA approval establishes market entry, regulatory hurdles continue at the international level. Approval timelines and reimbursement policies vary by country, affecting global sales velocity.

Market saturation and competitive threats

Entry of alternative treatments, such as faster-acting gepants or combination therapies, can erode ReyVow’s market share. Additionally, long-term safety data accumulation may influence prescribing patterns.

Emerging Trends Shaping Future Financial Outcomes

Shift Toward Personalized Migraine Treatment

The trend toward personalized medicine, via pharmacogenomics and tailored therapy, can either bolster ReyVow's adoption—especially among high-risk populations—or limit it if more targeted or combination strategies prove superior.

Advances in Digital Health Integration

Remote monitoring and digital patient engagement tools can enhance medication adherence and efficacy reporting, positively influencing revenue streams.

Conclusion: Strategic Outlook

ReyVow’s market dynamics hinge on a complex interplay of clinical positioning, competitive landscape, regulatory environment, and payer strategies. While initial adoption may be moderate, the drug’s unique mechanism and safety profile position it favorably in niche segments. The financial trajectory suggests potential for substantial revenues, contingent upon sustained clinical validation, effective marketing, and favorable reimbursement policies.

---

Key Takeaways

• ReyVow serves as a crucial treatment alternative for migraine patients contraindicated for triptans, filling a significant unmet need.
• Market penetration hinges on clinical acceptance, physician education, and reimbursement strategies, with early forecasts indicating moderate initial sales growth.
• Competitive pressures from gepants and CGRP therapies will influence market share, emphasizing the need for strategic differentiation.
• Long-term financial success depends on expanding global approvals, optimizing pricing, and demonstrating durable safety and efficacy.
• Emerging trends in personalized telehealth solutions present opportunities to augment ReyVow's market adoption and revenue potential.

---

FAQs

1. What distinguishes ReyVow from other migraine treatments?
ReyVow’s selective 5-HT1F receptor agonism offers effective migraine relief without vasoconstriction, making it suitable for patients who cannot use triptans due to cardiovascular risks.

2. How does ReyVow's market potential compare globally?
While primarily marketed in the U.S., global expansion hinges on regulatory approvals in Europe, Asia, and other regions, where migraine prevalence is high but treatment options vary.

3. What are the main barriers to ReyVow’s widespread adoption?
Barriers include physician familiarity, high treatment costs, insurance reimbursement complexities, and strong competition from established therapies like gepants and monoclonal antibodies.

4. How might future clinical trials influence ReyVow’s financial outlook?
Positive long-term safety and efficacy data could enhance prescriber confidence, expand indications, and improve market penetration, positively impacting revenues.

5. What strategies could Eli Lilly deploy to maximize ReyVow’s market success?
Eli Lilly can focus on targeted education campaigns, negotiate favorable reimbursement agreements, and accelerate international regulatory filings to broaden market access.

---

References

1. MarketsandMarkets. "Migraine Treatment Market by Product, Distribution Channel, and Region – Forecast to 2028."
2. Analyst Reports, 2023. "ReyVow Commercial Outlook and Market Penetration Strategies."